Healthcare Portfolio

We take a unique approach

The global population is aging at a record pace. A rapidly increasing number now demand life-improving and life-saving technologies. While patients demand novel drugs that can cure disease and save lives, governments and corporations also search for more cost-effective ways of delivering healthcare. Lux believes that the best chance of making a difference and a profit in healthcare is by combining groundbreaking technologies with focused, capital efficient businesses. Whether that be an effort to find vaccines for some of the world’s most lethal diseases or cost-effective new methods of treating cancer while maintaining patient quality of life, Lux’s healthcare investments seek to provide costs savings and solve unmet medical needs. Lux is creating companies and planting the seeds of meaningful innovation in healthcare, and, as a result, we believe it is well positioned to capture the fruits of the coming harvest.

Cerulean

Cerulean is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. Cerulean’s nanoparticle-based therapeutics allow for enhanced delivery of drugs, optimizing the location and release while minimizing toxicities. The company is currently targeting applications in oncology, with a lead compound in Phase II clinical trials.

PHOTO: Oliver Fetzer, CEO

Visit the website

View case study

Genocea Biosciences

Genocea was founded by Lux in 2006 as a spin-out of Harvard Medical School to commercialize key breakthroughs in vaccine discovery and development. Genocea has built a rapid screening platform that mimics the human immune system to identify antigens with the highest probability of generating protective immunity.

PHOTO: Chip Clark, CEO

Visit the website

Kala Pharmaceuticals

Kala Pharmaceuticals was founded by Lux as a spin-out of Johns Hopkins University to commercialize a proprietary drug delivery technology for penetrating mucus using nanotechnology. By utilizing this unique technology, Kala aims to address unmet therapeutic needs of various diseases and conditions in a fundamentally novel way.

Visit the website

Kereos

Kereos develops molecular imaging agents and targeted therapeutics that identify and attack cancer and cardiovascular disease earlier and more specifically than conventional methods. The company has been supported by over $15 million in government grants and is currently partnered with Bristol Myers Squibb, Dow Chemical, and Philips Medical Imaging.

Visit the website

Magen (acquired)

Magen Biosciences was focused on improving the health and appearance of human skin. The company was acquired by PPD, Inc [PPDI].

Visterra

Visterra rationally designs more effective therapeutics and vaccines based on a groundbreaking technology platform built around a unique structural understanding of how a virus interacts with human cells. The company has established proof of concept with a number of infectious diseases, including influenza.

Visit the website

« BACK TO PORTFOLIO

Case Study

CeruleanRethinking cancer therapy

Using the science of nanotechnology, Cerulean is developing a platform of potent new cancer drugs that selectively target tumors, burrowing their way into cancer cells while leaving the rest of the body unscathed. Early clinical results indicate the drugs have the potential to be effective across numerous cancer types, while improving both safety and quality-of-life for patients. The company’s lead drug is currently being evaluated in Phase II clinical trials for patients with advanced cases of lung cancer. The platform has also shown promise in delivering gene therapy to cancer cells.

Close X